文献速递心脑血管急症消化、代谢与肾脏急症

评估高血压管理激励措施的后果

Evaluating the Consequences of a Hypertension Management Incentive.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在大型医疗系统中,医生合同加入高血压控制质量指标与财务激励后,总体高血压人群的血压控制、用药调整和心血管住院无显著变化;但对初始收缩压140–145 mmHg的边缘性高血压患者,激励与更频繁复测血压、更多被记录为控制达标、更少的药物剂量上调及更高的卒中或ACS住院风险相关。

该准实验性双重差分研究比较了美国一家大型医疗系统中采纳与未采纳高血压控制(血压<140/90 mmHg)财务激励的初级保健诊所,纳入334 364例确诊高血压患者(平均年龄64.9岁,53.3%女性)的770 907次就诊,比较2021年(激励前)与2022–2023年(激励后)的临床决策和健康结局变化。总体人群中,激励与血压复测概率增加1.9个百分点(95%CI 0.7–3.1,P=0.002)相关,高血压控制、用药结局和心血管住院无统计学显著变化。在初始收缩压140–145 mmHg的边缘性高血压亚组中,激励与血压复测概率增加5.6个百分点(95%CI 2.9–8.3,P<0.001)、被记录为控制达标的概率增加4.1个百分点(95%CI 2.1–6.0,P<0.001)相关,同时现有降压药剂量上调的概率降低1.1个百分点(95%CI -2.0至-3.0,P=0.01),卒中或ACS住院的3个月风险增加0.25个百分点(95%CI 0.07–0.44,P=0.005),1年时超额风险增至0.52个百分点(95%CI 0.17–0.87,P=0.008)。作者认为,该质量指标与财务激励对总体高血压人群的测量结局影响很小,而在边缘性高血压患者中,激励与选择性复测血压导致的记录控制率增加、药物调整减少及心血管住院增加相关。

要点

  • 总体高血压人群中,财务激励与血压复测概率增加1.9个百分点(95%CI 0.7–3.1,P=0.002)相关,高血压控制、用药结局和心血管住院无统计学显著变化。
  • 初始收缩压140–145 mmHg的边缘性高血压患者中,激励与血压复测概率增加5.6个百分点(95%CI 2.9–8.3,P<0.001)及被记录为控制达标的概率增加4.1个百分点(95%CI 2.1–6.0,P<0.001)相关。
  • 同一边缘性高血压亚组中,现有降压药剂量上调的概率降低1.1个百分点(95%CI -2.0至-3.0,P=0.01)。
  • 边缘性高血压亚组中,卒中或ACS住院的3个月风险增加0.25个百分点(95%CI 0.07–0.44,P=0.005),1年时超额风险增至0.52个百分点(95%CI 0.17–0.87,P=0.008)。
  • 作者认为,该激励对总体高血压人群的测量结局影响很小,边缘性高血压患者中记录控制率增加与选择性复测血压、药物调整减少及心血管住院增加相关。

适用人群与场景

  • 纳入既往确诊高血压、年龄18至85岁、在符合条件的初级保健诊所就诊的患者。
  • 研究场景为美国一家大型医疗系统的初级保健诊所,非急诊或ICU场景。

诊断标准与关键阈值

  • 高血压控制的质量指标定义为血压<140/90 mmHg。
  • 边缘性高血压亚组定义为初始收缩压140–145 mmHg。

研究设计与关键结果

  • 研究类型为准实验性双重差分研究,纳入334 364例高血压患者(平均[SD]年龄64.9[12.6]岁;53.3%女性)及770 907次就诊,涉及103家初级保健诊所。
  • 2022年1月,63家诊所的医生合同引入高血压控制财务激励。
  • 总体人群中,激励与血压复测概率增加1.9个百分点(95%CI 0.7–3.1,P=0.002)相关,高血压控制、用药结局和心血管住院无统计学显著变化。
  • 边缘性高血压亚组中,激励与血压复测概率增加5.6个百分点(95%CI 2.9–8.3,P<0.001)及被记录为控制达标的概率增加4.1个百分点(95%CI 2.1–6.0,P<0.001)相关。
  • 边缘性高血压亚组中,现有降压药剂量上调的概率降低1.1个百分点(95%CI -2.0至-3.0,P=0.01)。
  • 边缘性高血压亚组中,卒中或ACS住院的3个月风险增加0.25个百分点(95%CI 0.07–0.44,P=0.005),1年时超额风险增至0.52个百分点(95%CI 0.17–0.87,P=0.008)。
  • 数据分析时间为2024年1月至2025年9月。

证据类型、等级与局限

  • 证据类型为准实验性双重差分研究。

对床旁实践的改变

  • 作者认为,在大型医疗系统中于医生合同加入质量指标和财务激励对总体高血压人群的测量结局影响很小。
  • 作者认为,对于边缘性高血压患者,激励与选择性复测血压导致的记录高血压控制率增加、药物调整减少及心血管住院增加相关。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Quality metrics with financial incentives are widely used, but their impact on clinical care and patient health remains challenging to isolate.

OBJECTIVE: To evaluate the association of a physician-facing quality metric and financial incentive for hypertension control (blood pressure <140/90 mm Hg) with clinical decisions and health outcomes.

DESIGN, SETTING, AND PARTICIPANTS: This quasi-experimental difference-in-differences study in a large US health system compared changes in outcomes at practices that did vs those that did not adopt the financial incentive before (2021) vs after (2022-2023) adoption. Participants included patients with previously diagnosed hypertension, aged 18 to 85 years, with encounters at eligible primary care practices. Data were analyzed from January 2024 to September 2025.

EXPOSURES: Patient exposure to the financial incentive was determined by which practice delivered their care.

MAIN OUTCOMES AND MEASURES: Initial and final systolic blood pressure at the primary care encounter and number of measurements, antihypertensive prescriptions and dose adjustments, and hospitalizations for incident stroke or acute coronary syndrome (ACS).

RESULTS: The study included 334 364 patients with hypertension (mean [SD] age, 64.9 [12.6] years; 53.3% female) and their 770 907 encounters at 103 primary care practices. In January 2022, the hypertension control financial incentive was introduced in physician contracts for 63 of these practices. In the overall population of patients with hypertension, the financial incentive was associated with an increased probability of blood pressure remeasurement (by 1.9 [95% CI, 0.7-3.1] percentage points [pp]; P = .002) with no statistically significant change in hypertension control, medication outcomes, or cardiovascular hospitalizations. For the subgroup of patients with marginally high blood pressure (defined as initial systolic blood pressure of 140-145 mm Hg), the financial incentive was associated with an increased probability (by 4.1 [95% CI, 2.1-6.0] pp; P < .001) that blood pressure was documented as controlled, subsequent to an increased probability of blood pressure remeasurement (by 5.6 [95% CI, 2.9-8.3] pp; P < .001). The probability of an existing antihypertensive medication dose being increased was reduced (-1.1 [95% CI, -2.0 to -3.0] pp; P = .01), and the 3-month risk of hospitalization for stroke or ACS increased (by 0.25 [95% CI, 0.07-0.44] pp; P = .005), with excess risk growing to 0.52 pp (95% CI, 0.17-0.87 pp; P = .008) pp at 1 year.

CONCLUSIONS AND RELEVANCE: This study's findings suggest that the addition a quality metric and financial incentive to physicians' contracts in a large health system had little impact on measured outcomes in the overall population of patients with hypertension. For patients with marginally high blood pressure, the incentive was associated with increased documented hypertension control because of selective remeasurement of blood pressure, decreased medication adjustments, and increased cardiovascular hospitalizations.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Boone C, Robicsek A. Evaluating the Consequences of a Hypertension Management Incentive. JAMA Intern Med. 2026. PMID: 42223964. doi:10.1001/jamainternmed.2026.1637

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。